Use of fak inhibitor in preparation of drug for treating tumors having nras mutation
AssigneeInxmed (Nanjing) Co., Ltd.
InventorsZaiqi WANG, Jiangwei ZHANG, Jun JIANG
Life of this patent
Estimating the term…
Abstract
A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is BI853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.
Claims15
1-7. (canceled)
A method of treating tumors having an NRAS mutation comprising administering to an individual an effective amount of a FAK inhibitor.
17-23. (canceled)
Dependencies are inferred from the claim text.